UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease

Athauda, D; Foltynie, T; (2018) Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease. Neuropharmacology , 136 (B) pp. 260-270. 10.1016/j.neuropharm.2017.09.023. Green open access

[img]
Preview
Text
Foltynie_Protective effects of GLP-1 - Revision.pdf - ["content_typename_Accepted version" not defined]

Download (674kB) | Preview

Abstract

There is increasing interest in the potential role of glucagon-like peptide-1 (GLP-1) receptor agonists as neuroprotective treatments in neurodegenerative diseases including Parkinson's disease following the publication of the results of the Exenatide-PD trial. Of the current GLP-1 receptor agonists already licensed to treat Type 2 diabetes several including exenatide, liraglutide and lixisenatide are the subject of ongoing clinical trials in PD. The underlying rationale for using drugs licensed and effective for T2DM in PD patients therefore needs to be scrutinized, and the results obtained to date critically reviewed. We review the relationship between insulin resistance and Parkinson's disease, the implications on pathogenesis and the efforts to reposition GLP-1 agonists as potential treatments for Parkinson's disease and give an overview of the pre-clinical and clinical data supporting the use of exenatide in Parkinson's disease with a discussion regarding possible mechanisms of action.

Type: Article
Title: Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.neuropharm.2017.09.023
Publisher version: http://doi.org/10.1016/j.neuropharm.2017.09.023
Language: English
Additional information: © 2017 Elsevier Ltd. All rights reserved. This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Exenatide, Glucagon-like peptide-1 agonist, Insulin resistance, Neuroprotection, Parkinson's disease
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Clinical and Movement Neurosciences
URI: http://discovery.ucl.ac.uk/id/eprint/10025037
Downloads since deposit
91Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item